Caffeine Withdrawal, Energy, Focus
Conditions
Brief summary
Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.
Detailed description
Following enrollment to the study, participants will abstain from any products containing caffeine, for 3 days. On the night of the 3rd day of caffeine abstinence, participants will fast overnight (\ 10 hours) The morning after the fast, participants will complete the Day 1 baseline questionnaire. Participants will then consume Test Product A and complete questionnaires 30, 60, 90, and 120 minutes after ingestion. Test Products should be consumed in a fasted state, and 1-hour post-ingestion participants will consume a standardized meal (See Section 6.3). On Day 2, participants will consume Test Product A again but will not complete any questionnaires. The product should be consumed in a fasted state and participants will consume the standardized meal 60 minutes post-ingestion. On Day 3, participants will consume Test Product A in a fasted state and will again consume the standardized meal 1-hour following ingestion of the product. Participants will complete questionnaires 30, 60, 90, and 120 minutes after ingestion. Participants will then have a 3-day washout period with no products consumed or questionnaires completed. Following the washout period, the intervention cycle will be repeated with Test Product B and, subsequently, Test Product C. The questionnaires will consist of study-specific surveys and a cognitive assessment battery.
Interventions
For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
Sponsors
Study design
Eligibility
Inclusion criteria
* Aged between 18-35 * Willing to abstain from caffeine-containing beverages and foods during the duration of the study * Recreationally active; currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months
Exclusion criteria
* Body Mass Index: \>29.9kg/m2 * Inability to adhere to protocol guidelines (e.g., caffeine, alcohol, tobacco) * Regular tobacco use * Illicit drug use (e.g., growth hormone, testosterone, etc.) * A diagnosed medical condition under the care of a physician (e.g. type 2 diabetes) Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial * Individuals on medications known to affect caffeine metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications) * Participants who are amenorrheic (females only) * Inability to comply with the study protocol as judged by the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in scores on a cognitive assessment Double Trouble. [Time Frame: Baseline to Day 3 of each test cycle] | 18 days | Participants will independently complete a cognitive assessment battery at home on their computer or tablet. Double Trouble is a 90-second timed test. Based on a classic Stroop test, Double Trouble measures selective attention, processing speed, and the brain's ability to focus on specific information when presented with conflicting and layered stimuli. |
| Changes in scores on a cognitive assessment Feature Match. [Time Frame: Baseline to Day 3 of each test cycle] | 18 days | Participants will independently complete a cognitive assessment battery at home on their computer or tablet. Feature Match is a 90-second timed test. Feature Match is a focus and processing task that requires surveying an increasingly difficult array of information and rapidly assessing the correct response while holding previously processed and detailed information in attention. |
| Changes in scores on a cognitive assessment Grammatical Reasoning. [Time Frame: Baseline to Day 3 of each test cycle] | 18 days | Participants will independently complete a cognitive assessment battery at home on their computer or tablet. Grammatical Reasoning is a 90-second timed test. Grammatical Reasoning is a deductive reasoning task that requires quickly interpreting phrases and making logical conclusions from understanding. Variation between text and shapes on screen requires holding key information in short-term memory to properly complete the task, leveraging the same parts of the brain that enable an individual to remain focused between varied stimuli. |
| Changes in scores on a cognitive assessment Digit Span. [Time Frame: Baseline to Day 3 of each test cycle] | 18 days | Participants will independently complete a cognitive assessment battery at home on their computer or tablet. Digit Span is a 3-4 minute performance based test. Increasing in length after each successful attempt, Digit Span requires users to focus on displayed numbers, hold them in short-term memory, and repeat them back correctly, thereby showing cognitive flexibility and the brain's ability to perform memory and attention-related tasks without error. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of the side effects of caffeine withdrawal. [Baseline to Endline] | 18 days | Decrease in symptoms of caffeine withdrawal including jitters, fatigue, drowsiness, irritability, brain fog, and low alertness. This will be reported via participant-reported questionnaires. Incidence and severity of side effects will be reported using a Likert scale (0-5 point scale) with 0=least severe and 5=most severe. |
Countries
United States